U.S. License Holder:
Coherus
Date of License:
November-02-2018
Last Update:
February-28-2021
FDA-Approved Indications
UDENYCA (pegfilgrastim-cbqv) is a leukocyte growth factor indicated to decrease the incidence of infection, as manifested by febrile neutropenia, in patients with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a clinically significant incidence of febrile neutropenia.
Approved Foreign Follow-On Biologics / Biosimilars
Biosimilars Approved In The E.U.
Udenyca® (Coherus Biosciences) (September-2018)